Difference between revisions of "Melphalan for Injection-Hepatic Delivery System (Hepzato Kit)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Nitrogen mustard, alkylator ==Diseases for which it is established== *Uveal melanoma ==History of changes in FDA indication== *2...") |
Warner-admin (talk | contribs) m (Warner-admin moved page Melphalan for Injection/Hepatic Delivery System (Hepzato Kit) to Melphalan for Injection-Hepatic Delivery System (Hepzato Kit) without leaving a redirect: Breaking special character) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 10: | Line 10: | ||
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Hepzato | *'''Brand name:''' Hepzato | ||
| + | |||
| + | ==References== | ||
| + | #FOCUS<sub>HCC</sub>: NCT02678572 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Latest revision as of 00:15, 18 October 2023
General information
Class/mechanism: Nitrogen mustard, alkylator
Diseases for which it is established
History of changes in FDA indication
- 2023-08-14: Initial approval as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. (Based on FOCUSHCC)
Also known as
- Brand name: Hepzato
References
- FOCUSHCC: NCT02678572